Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population

Neuzillet, Y.; Tillou, X.; Mathiéu, Romain; Long, Jean-Alexandre; Gigante, Maddalena; Paparel, P.; Poissonnier, L.; Baumert, H.; Escudier, Bernard; Lang, Hervé; Rioux‐Leclercq, Nathalie; Bigot, Pierre; Bernhard, Jean-Christophe; Albigès, Laurence; Bastien, Laurence; Petit, Jacques; Saint, F.; Bruyère, F.; Boutin, Jean-Michel; Brichart, N.; Karam, Georges; Branchereau, J.; Ferrière, Jean-Marie; Wallerand, Hervé; Barbet, Sébastien; Elkentaoui, Hicham; Hubert, Jacques; Feuillu, B.; Theveniaud, Pierre-Etienne; Villers, Arnauld; Zini, Luca; Descazeaux, Aurélien; Rouprêt, Morgan; Barrou, B.; Fehri, K.; Lebrét, Thierry; Tostain, Jacques; Terrier, Jean-Étienne; Terrier, N.; Martin, Lucille; Dugardin, F.; Galliot, I.; Staerman, F.; Azémar, Marc; Irani, Jacques; Tisserand, B.; Timsit, Marc‐Olivier; Sallusto, Fédérico; Rischmann, P.; Guy, Laurent; Valéri, Antoine; Deruelle, C.; Azzouzi, Abdel-Rahmène; Chautard, Denis; Méjean, Arnaud; Salomon, Laurent; Rigaud, J.; Pfister, Christian; Soulié, M.; Kleinclauss, F.; Badet, Lionel; Patard, Jean‐Jacques

doi:10.1016/j.eururo.2011.02.035

Cited by 87 publications

(74 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…93 than sporadic RCCs. 97 They also had a wide spectrum of distinct pathologic features and prevalence that varies by dialysis vintage, with ACKD-associated RCC being most common in patients who have been on dialysis for ≥10 years. 98 However, the exact pathophysiology by which the uraemic state, dialysis, and transplantation can cause malignant transformation in the kidney remains unknown and is likely multifactor ial.…”

Section: Future Researchmentioning

confidence: 99%

Risk of chronic kidney disease after cancer nephrectomy

Li¹,

Lau²,

Rhee³

et al. 2014

Nat Rev Nephrol

View full text Add to dashboard Cite

The incidence of early stage renal cell carcinoma (RCC) is increasing and observational studies have shown equivalent oncological outcomes of partial versus radical nephrectomy for stage I tumours. Population studies suggest that compared with radical nephrectomy, partial nephrectomy is associated with decreased mortality and a lower rate of postoperative decline in kidney function. However, rates of chronic kidney disease (CKD) in patients who have undergone nephrectomy might be higher than in the general population. The risks of new-onset or accelerated CKD and worsened survival after nephrectomy might be linked, as kidney insufficiency is a risk factor for cardiovascular disease and mortality. Nephron-sparing approaches have, therefore, been proposed as the standard of care for patients with type 1a tumours and as a viable option for those with type 1b tumours. However, prospective data on the incidence of de novo and accelerated CKD after cancer nephrectomy is lacking, and the only randomized trial to date was closed prematurely. Intrinsic abnormalities in non-neoplastic kidney parenchyma and comorbid conditions (including diabetes mellitus and hypertension) might increase the risks of CKD and RCC. More research is needed to better understand the risk of CKD post-nephrectomy, to develop and validate predictive scores for risk-stratification, and to optimize patient management.

show abstract

Section: Future Researchmentioning

confidence: 99%

Risk of chronic kidney disease after cancer nephrectomy

Li¹,

Lau²,

Rhee³

et al. 2014

Nat Rev Nephrol

View full text Add to dashboard Cite

show abstract

“…3 Compared with the general population, the incidence of RCC might be higher in the ESRD population, the underlying biology might be different, and the clinical and pathological features might be more favorable. 4 Patients with ESRD are often excluded from prospective clinical trials because of their altered pharmacokinetics.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Patients With Metastatic Renal Cell Carcinoma and End-Stage Renal Disease Receiving Dialysis and Targeted Therapies: A Single Institution Experience

Shetty¹,

Matrana

Atkinson

et al. 2014

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Data are limited regarding outcomes in patients with end-stage renal disease (ESRD) and metastatic renal cell carcinoma (mRCC) receiving targeted therapy. We retrospectively identified patients with mRCC and ESRD treated at the University of Texas M.D. Anderson Cancer Center from 2002 to 2012. Fourteen patients were identified with a median number of targeted therapies (TTs) per patient of 3 (range, 1–4). Outcomes in patients with mRCC and ESRD were similar to those reported in patients with normal kidney function. Introduction Limited data are available regarding patients with renal cell carcinoma and ESRD treated with TTs. The objective of this study was to explore the tolerability and safety of TT in patients with mRCC and ESRD. Patients and Methods We retrospectively identified patients with mRCC and ESRD treated at the University of Texas M.D. Anderson Cancer Center from 2002 to 2012. Patient characteristics including demographic, histology, treatment, and adverse events are reported. Duration of treatment (TOT) was determined from date of drug initiation to discontinuation. Overall survival (OS) was determined from initiation of TT to death. Statistics are descriptive. Results Fourteen patients were identified. Ten patients had clear-cell histology and 4 had papillary histology. The median number of TTs per patient was 3 (range, 1–4) with median TOT of 28 months for all TTs. Eighty-eight percent of all toxicities were Grade 1 to 2; no Grade 4 toxicities were noted. Treatment discontinuations included 3 patients treated with sorafenib due to hand-foot syndrome, intolerable fatigue, and squamous cell skin cancer development; 2 patients treated with pazopanib due to intolerable fatigue and increased transaminase levels; and 1 patient treated with everolimus due to pneumonitis. Eight patients died from progressive disease. Median OS from initiation of TT was 28.5 months and 35 months from time of diagnosis. Conclusion Toxicities were mild to moderate and consistent with those reported in previous studies. TTs appear to be safe, well tolerated and produce antitumor response in patients with mRCC and ESRD receiving dialysis.

show abstract

“…17 These tumors are generally small and asymptotic, and their diagnosis is usually incidental. It also seems that RCC development in the native kidney of renal transplant recipients is an early event, frequently observed within 4 to 5 years after transplant.…”

Section: Discussionmentioning

confidence: 99%

De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-Center Experience

Karczewski

Rzymski²,

Karczewski³

2012

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Our study aimed to determine the incidence of de novo renal cell carcinoma in the native kidneys of patients transplanted at our center and to identify possible risk factors. Materials and Methods: We performed a retrospective, single-center cohort study, which included patients transplanted at the District Hospital in Poznan, Poland, during 1994-2011, among whom 836 were selected. Sixty-three patients with confirmed de novo cancer were found. Of those, 11 had renal cell carcinoma in the native kidney (1.3%) and 2 in the transplanted kidney (0.2%). Results: Mean follow-up was 10 ± 3.2 years. Mean age at renal cell carcinoma diagnosis was 52 ± 9.4 years, and mean time from transplant was 3 ± 2.6 years. A statistical analysis showed no significant differences in demographic or clinical characteristics between renal cell carcinoma and noncancer group, except for the prevalence of male sex and smoking in the cancer group (P < .05). Conclusions: Renal cell carcinoma development in the native kidney seems to be an early event, frequently observed within 4 to 5 years after transplant. We believe that kidneys in renal transplant recipients should be routinely screened by ultrasound for early diagnosis.

show abstract

Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population

Cited by 87 publications

References 25 publications

Risk of chronic kidney disease after cancer nephrectomy

Risk of chronic kidney disease after cancer nephrectomy

Outcomes of Patients With Metastatic Renal Cell Carcinoma and End-Stage Renal Disease Receiving Dialysis and Targeted Therapies: A Single Institution Experience

De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-Center Experience

Contact Info

Product

Resources

About